Trial | NCT01525017  Report issue

Title

A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer
A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    12
The primary objective of this study is to answer the question "Is it possible to inject the Combig-DC vaccine in a renal tumour without getting unacceptable side effects"? Patients newly diagnosed with metastatic renal cell carcinoma will get Combig-DC vaccinations at two occasions in a two weeks period (day 1 and day 14). After another two weeks the kidney will be eliminated. Adverse events will be registered, as well as changes in vital signs(heart rate, blood pressure and body temperature) and lab parameters. Immunologic response will be evaluated by measuring immunologic markers in blood and tumour tissue, and measuring the size of the metastases three months after nephrectomy.
Study Started
Feb 29
2012
Primary Completion
Dec 31
2013
Study Completion
Dec 31
2013
Last Update
Oct 12
2015
Estimate

Biological Combig-DC (allogeneic dendritic cells) Cancer Vaccine

Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).

Combig-DC Cancer Vaccine Experimental

Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.

Criteria 

Inclusion Criteria:

Be informed of the nature of the study and have provided written informed consent
At least 18 years of age.
Diagnosis of renal cell carcinoma with at least one distant metastasis, and/or one distant lymph node metastasis.
Tumor size (renal cell carcinoma; primary tumor) at least 4.0 cm in longest diameter as measured by CT. Distant metastasis at least 1 cm diameter as measured by CT or a distant lymph node metastasis at least 2,5 cm diameter as measured by CT. Clinical stage 'T1b or more; NX; M1'

Adequate hematological parameters, i.e:

B-Leukocyte count ≥ 4.5 x 109/L B-Platelet count ≥ 150 x109/L B-Haemoglobin ≥ 100 g/L

Women of Childbearing Potential (WOCBP) should use adequate contraception (oral or injectable contraceptives, hormone releasing intrauterine device) throughout the study period.

Exclusion Criteria:

Performance status > ECOG 2 after optimization of analgesics
Adequate coagulation parameters, i.e: P-Prothrombin complex (PK), P-APT time
Ongoing treatment with systemic corticosteroids (inhaled, intranasal and local steroids accepted) within 28 days before first vaccination.
Previously known or ongoing active autoimmune disease which requires treatment with systemic immunosuppressive agents. E.g. inflammatory bowel disease, multiple sclerosis, sarcoidosis, psoriasis, autoimmune hemolytic anemia, rheumatoid arthritis, SLE, vasculitis, Sjögren's syndrome, scleroderma, autoimmune hepatitis, and other rheumatological diseases.
Patients with previous or ongoing skin malignancy (basal-cell carcinoma, squamous cell carcinoma, melanoma), other hematological or solid malignancy or blood dysfunctions.
Ongoing infection that requires treatment with antibiotics.
Known major reaction/adverse event in connection with previously made vaccination (e.g. asthma, anaphylaxis or other serious reaction)
Known malignancy in CNS.
Active or latent virus disease (HIV, HBV and HCV).
Ongoing pregnancy or lactation. Females needs to have negative pregnancy test at screening visit.
Life expectancy less than 3 months.
Concomitant exposure to other investigational products.
Any reason that, in the opinion of the investigator, contraindicates that the patient participates in the study.
No Results Posted